New Data on 2 Alzheimer’s Drugs Alters Hope and Expectation
Thursday, July 23, 2015 - 00:40
in Mathematics & Economics
Solanezumab, from Eli Lilly, is getting another look for mild cases, and Biogen said data from a small group taking aducanumab showed mixed results.